The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia.
Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo alpha-tocopherol level of 1,896 +/- 643 micrograms/dl, and a neomycin alpha-tocopherol concentration of 1,449 +/- 451 micrograms/dl (p less than .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 +/- 614 micrograms/dl (p less than .05 from placebo). Normal plasma alpha-tocopherol ranges from 400-1,000 micrograms/dl. Neomycin treatment reduces but does not normalize elevated levels of alpha-tocopherol found in Type II hyperlipoproteinemia.
D008078:Cholesterol, LDL / Q000097:blood; D004032:Diet; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood*; D008055:Lipids / Q000097:blood; D008297:Male; D009355:Neomycin / Q000494:pharmacology*; D014810:Vitamin E / Q000097:blood*
D008078:Cholesterol, LDL; D008055:Lipids; D014810:Vitamin E; D009355:Neomycin